Preclinical characterization of SHR6390, a novel CDK 4/6 inhibitor, in vitro and in human tumor xenograft models

Inhibition of the cyclin‐dependent kinase (CDK) 4/6‐retinoblastoma (RB) pathway is an effective therapeutic strategy against cancer. Here, we performed a preclinical investigation of the antitumor activity of SHR6390, a novel CDK4/6 inhibitor. SHR6390 exhibited potent antiproliferative activity agai...

Descripción completa

Detalles Bibliográficos
Autores principales: Long, Fei, He, Ye, Fu, Haoyu, Li, Yun, Bao, Xubin, Wang, Quanren, Wang, Yigang, Xie, Chengying, Lou, Liguang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6447953/
https://www.ncbi.nlm.nih.gov/pubmed/30724426
http://dx.doi.org/10.1111/cas.13957

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6447953/
https://www.ncbi.nlm.nih.gov/pubmed/30724426
http://dx.doi.org/10.1111/cas.13957

Ejemplares similares